Last reviewed · How we verify
Intravenous acetominophen — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Intravenous acetominophen (Intravenous acetominophen) — The University of Texas Medical Branch, Galveston.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intravenous acetominophen TARGET | Intravenous acetominophen | The University of Texas Medical Branch, Galveston | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intravenous acetominophen CI watch — RSS
- Intravenous acetominophen CI watch — Atom
- Intravenous acetominophen CI watch — JSON
- Intravenous acetominophen alone — RSS
Cite this brief
Drug Landscape (2026). Intravenous acetominophen — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-acetominophen. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing